What Are CDK4/6 Inhibitors?

A cell divides in stages, and it has to pass checkpoints between them. CDK4 and CDK6 are cyclin-dependent kinases, enzymes that push a cell past one of those checkpoints and into copying its DNA.

The National Cancer Institute (NCI) explains why blocking them helps in breast cancer. CDK4 and CDK6 "can serve as dual threats, fueling the progression of breast tumors and helping to make them resistant to commonly used treatments like aromatase inhibitors."

That second half is the reason these drugs are almost always given with endocrine therapy rather than instead of it. The endocrine drug removes the hormone signal. The CDK4/6 inhibitor blocks the escape route the tumor uses to keep dividing anyway.

All three are pills. Their approved uses are not the same, and the differences are not trivia.

Palbociclib (Ibrance). NCI lists it for hormone receptor positive, HER2 negative breast cancer that has spread, in two settings: "with fulvestrant in adults whose cancer has gotten worse after treatment with hormone therapy," and "with an aromatase inhibitor in postmenopausal women and in men who have not been treated with hormone therapy."

Ribociclib (Kisqali). NCI lists it "with an aromatase inhibitor in women who have stage II or stage III early breast cancer that is at high risk of coming back," "with an aromatase inhibitor in women whose cancer has spread and has not been treated with hormone therapy," and "with fulvestrant" in advanced disease.

Abemaciclib (Verzenio). NCI lists it "with tamoxifen citrate or an aromatase inhibitor as adjuvant therapy" for early disease with lymph node involvement and high recurrence risk. In advanced disease, it is listed with fulvestrant after prior hormone therapy, alone after both hormone therapy and chemotherapy, and with an aromatase inhibitor as "first-line hormone therapy in men and postmenopausal women."

Read those side by side. Only abemaciclib is listed as a single agent. Only two are listed for use after surgery. NCI's ribociclib summary lists women, while palbociclib and abemaciclib summaries name men explicitly. If someone tells you these drugs are interchangeable, ask which label they are reading.

For years this class was for metastatic disease. That has moved.

On September 17, 2024, the Food and Drug Administration (FDA) approved ribociclib with an aromatase inhibitor for "HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence."

The evidence came from NATALEE, a trial of 5,101 people. The main measure was invasive disease-free survival, meaning time without the cancer returning as invasive disease. At 36 months it was 90.7% with ribociclib plus a nonsteroidal aromatase inhibitor, versus 87.6% with the aromatase inhibitor alone. The hazard ratio was "0.749 (95% CI: 0.628, 0.892)."

Sit with those numbers. The absolute gap at three years is about 3 percentage points. The relative reduction is about 25%. Both are true, and which one you focus on legitimately changes how a person feels about several years of a daily pill.

On June 24, 2026, FDA approved palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for "maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment."

That came from PATINA, which randomly assigned 518 patients. Progression-free survival improved with a hazard ratio of 0.76 (95% CI: 0.59, 0.97), p=0.0134. Overall survival data were still immature.

The takeaway for patients: this class is no longer only an HR-positive, HER2-negative story. Ask what your current HER2 status is and whether it changes your options.

Two examples FDA specifies. Palbociclib is "125 mg orally once daily for 21 consecutive days, followed by seven days off," in a 28-day cycle. Ribociclib in the early-breast-cancer setting is "400 mg (two 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off in 28-day treatment cycles." Both quotes are the label's wording. What you swallow is whatever your breast team prescribed, and the off week is part of the schedule.

Do not assume your drug follows that pattern. Ask for your calendar in writing, including which week is the off week and which days your blood counts get checked.

One practical detail people miss: FDA's ribociclib instructions say to refrigerate until dispensed, then store at room temperature for up to 2 months after dispensing. Ask your pharmacy to write the storage rule on the bag.

Diarrhea with abemaciclib. In the MONARCH 3 trial of about 500 postmenopausal women, NCI reports diarrhea affected roughly 80% of patients. NCI describes it as "usually manageable... with commonly used medications and/or reductions in the abemaciclib dose." In that trial, about 20% of participants stopped treatment because of side effects, and more than 40% needed a dose reduction. Have an antidiarrheal medicine and a plan in hand on day one, not on day nine.

Low neutrophils. FDA lists neutropenia among the warnings for palbociclib. Neutrophils are the white cells that fight bacteria. This is why counts are checked on a set schedule and why the off week exists.

Lung inflammation. FDA also lists interstitial lung disease and pneumonitis as warnings for palbociclib. New or worsening cough, breathlessness, or chest tightness is a same-day call, not a wait-and-see.

Pregnancy risk. FDA lists embryo-fetal toxicity. Contraception planning belongs in the first conversation.

For advanced disease, teams watch symptoms, exams, and scans. NCI reports that in MONARCH 3, tumors shrank in 59% of the abemaciclib group versus 44% of the comparison group.

For early disease after surgery, there is nothing to measure shrinking. The benefit is statistical, spread over years, and invisible day to day. That is worth naming out loud, because it makes staying on a pill with side effects genuinely harder.

Which of the three am I getting, and why that one? Is my goal lowering recurrence risk after surgery, or controlling advanced disease? Which endocrine drug is it paired with? What is my exact schedule, including the off week? When are blood counts drawn? What is my diarrhea plan, in writing, with a prescription? What symptom means I call the same day? How long is treatment planned to last? What are the storage rules for my pills? If side effects are bad, is dose reduction an option before stopping?

Start with Hormone Therapy for Breast Cancer, Breast Cancer Treatment by Stage, and Targeted Therapy vs Chemotherapy.

• https://www.cancer.gov/news-events/cancer-currents-blog/2018/abemaciclib-fda-breast-cancer-first-line
• https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib
• https://www.cancer.gov/about-cancer/treatment/drugs/ribociclib
• https://www.cancer.gov/about-cancer/treatment/drugs/abemaciclib
• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-kisqali-aromatase-inhibitor-and-kisqali-femara-co-pack-early-high-risk-breast-cancer
• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance